Cipla Ltd
CIPLA
Company Profile
Business description
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
Contact
Ganpatrao Kadam Marg
Cipla House, Peninsula Business Park
Lower Parel
MumbaiMH400 013
INDT: +91 2224826000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
45,189
Stocks News & Analysis
stocks
Corning’s AI fiber boom is real, but its stock price may be getting out of hand
Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,941.90 | 7.50 | -0.08% |
| CAC 40 | 8,141.92 | 15.90 | -0.19% |
| DAX 40 | 24,083.53 | 45.45 | -0.19% |
| Dow JONES (US) | 49,167.79 | 62.92 | -0.13% |
| FTSE 100 | 10,321.09 | 57.99 | -0.56% |
| HKSE | 25,752.60 | 173.05 | -0.67% |
| NASDAQ | 24,887.10 | 50.50 | 0.20% |
| Nikkei 225 | 59,933.02 | 604.34 | -1.00% |
| NZX 50 Index | 12,745.06 | 129.88 | -1.01% |
| S&P 500 | 7,173.91 | 8.83 | 0.12% |
| S&P/ASX 200 | 8,717.70 | 3.50 | -0.04% |
| SSE Composite Index | 4,083.47 | 2.87 | -0.07% |